微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 18.69% | -2.49% | -2.44% | 142/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 19.16% | -4.37% | 5.26% | 139/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 18.2% | -2.9% | -3.09% | 143/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 18.78% | -22.1% | -2.02% | 137/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 19.17% | -18.4% | -4.32% | 134/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 20.04% | -19.94% | 6.88% | 135/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 18.75% | -31.67% | -22.25% | 132/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 24.11% | -18.33% | 2.63% | 130/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 23.5% | -19.23% | -6.13% | 131/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.03% | -15.94% | -8.77% | 129/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 27.44% | -12.57% | -7.07% | 121/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 29.52% | 8.73% | 1.49% | 121/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 29.09% | 11.78% | -2.3% | 121/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 29.78% | 14.52% | -5.11% | 121/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 31.38% | 14.76% | 15.57% | 115/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.15% | 0.43% | 4.34% | 127/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 26.02% | -7.21% | 0.09% | 122/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 26% | -11.22% | -4.91% | 128/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 27.34% | -5.95% | 1.14% | 116/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 27.04% | -10.52% | -3.6% | 131/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 28.05% | -3.31% | -4.24% | 117/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.29% | 4.38% | 0.73% | 125/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 29.08% | 2.59% | -3.77% | 107/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 30.22% | -9.64% | 4.17% | 126/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 29.01% | -8.42% | 3.38% | 105/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 28.06% | -11.01% | -1% | 116/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 28.34% | -12.07% | -15.24% | 98/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 33.44% | 10.98% | 5.58% | 111/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 31.67% | 13.41% | 0.46% | 92/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 31.53% | 13.18% | -2.18% | 98/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 32.23% | 12.88% | 6.97% | 87/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 30.13% | 7.3% | 7.89% | 113/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 27.93% | 2.98% | 0.26% | 90/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.86% | 1.43% | -2.44% | 94/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 28.56% | 5.85% | 1.68% | 88/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 28.08% | 12.59% | 3.55% | 106/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.12% | 12.23% | -1.26% | 83/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 27.46% | 19.9% | 1.81% | 83/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.98% | 10.51% | 8.16% | 70/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 24.94% | 7.23% | 3.21% | 98/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 24.17% | 8.25% | 5.49% | 72/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 22.91% | 6.64% | -6.16% | 82/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 24.41% | 6.02% | 4.95% | 67/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |